Linkers: An Assurance for Controlled Delivery of Antibody-Drug Conjugate
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
As one of the major therapeutic options for cancer treatment, chemotherapy has limited selectivity against cancer cells. Consequently, this therapeutic strategy offers a small therapeutic window with potentially high toxicity and thus limited efficacy of doses that can be tolerated by patients. Antibody-drug conjugates (ADCs) are an emerging class of anti-cancer therapeutic drugs that can deliver highly cytotoxic molecules directly to cancer cells. To date, twelve ADCs have received market approval, with several others in clinical stages. ADCs have become a powerful class of therapeutic agents in oncology and hematology. ADCs consist of recombinant monoclonal antibodies that are covalently bound to cytotoxic chemicals via synthetic linkers. The linker has a key role in ADC outcomes because its characteristics substantially impact the therapeutic index efficacy and pharmacokinetics of these drugs. Stable linkers and ADCs can maintain antibody concentration in blood circulation, and they do not release the cytotoxic drug before it reaches its target, thus resulting in minimum off-target effects. The linkers used in ADC development can be classified as cleavable and non-cleavable. The former, in turn, can be grouped into three types: hydrazone, disulfide, or peptide linkers. In this review, we highlight the various linkers used in ADC development and their design strategy, release mechanisms, and future perspectives.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glutathione Metabolism and Its Implications for Health
Wu, G., Lupton, J. R., Turner, N. D., Fang, Y.-Z., & Yang, S. (2004) · The Journal of Nutrition · doi:10.1093/jn/134.3.489 · Cited by 3,842 · cited 1×
“Glutathione is a low molecular weight thiol present in the cytoplasm (1–10 mmol/L) and extracellular environment (2–20 μmol/L in plasma) [6,20,83,84].”
BackgroundStrategies and challenges for the next generation of antibody–drug conjugates
Beck, A., Goetsch, L., Dumontet, C., & Corvaïa, N. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.268 · Cited by 2,271
Antibody–Drug Conjugates: An Emerging Concept in Cancer Therapy
Chari, R. V. J., Miller, M. L., & Widdison, W. C. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201307628 · Cited by 930
Solid-phase peptide synthesis: from standard procedures to the synthesis of difficult sequences
Coin, I., Beyermann, M., & Bienert, M. (2007) · Nature Protocols · doi:10.1038/nprot.2007.454 · Cited by 638 · cited 9×
“ADC Structure Linkage Type Cleavage Mechanism Products Formed Cleavage Site pH sensitive Hydrolysis O R HN NH2 + Lysosome/Endosome [57– 60] Reduction sensitive Reduction Cytoplas [56,61–63] Peptide based linkage Proteolysis Lysosome [64–67] β-glucoronide Glyosidase 1, 6-Elimination Lysosome [68,69] Pharmaceutics 2022,…”
BackgroundInfluentialAntibody–drug conjugates: Recent advances in linker chemistry
Su, Z., Xiao, D., Xie, F., Liu, L., Wang, Y., Fan, S., Zhou, X., & Li, S. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.03.042 · Cited by 403 · cited 3×
“For instance, photo-sensitive ADC linkers and biorthogonal cleavable linkers are emerging classes that are still under study [126].”
BackgroundInfluentialCathepsin B as a cancer target
Gondi, C. S., & Rao, J. S. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.740461 · Cited by 399
Belantamab Mafodotin: First Approval
Markham, A. (2020) · Drugs · doi:10.1007/s40265-020-01404-x · Cited by 145
Cited by
Antibody–Drug Conjugates (ADCs): current and future biopharmaceuticals
Wang, R., Hu, B., Pan, Z., Mo, C., Zhao, X., Liu, G., Hou, P., Cui, Q., Xu, Z., Wang, W., et al. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01704-3 · Cited by 285
The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development
Colombo, R., Tarantino, P., Rich, J. R., LoRusso, P. M., & de Vries, E. G. E. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0708 · Cited by 254
De, S. K. (2023) · Medicines for Cancer · doi:10.1016/b978-0-443-13312-1.00009-x · Cited by 1
Metadata
- Authors
- Sheyi, R., de la Torre, B. G., & Albericio, F.
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2022-02-11
- Volume
- 14
- Issue
- 2
- Pages
- 396
- ISSN
- 1999-4923 (ISSN-L)
- OpenAlex
- W4211172653
- Cited by
- 224
- References
- 7
- FWCI
- 21.88
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.